新諾威(300765.SZ):擬向恩必普藥業出售中諾醫藥科技全部股權
格隆匯 3 月 4日丨新諾威(300765.SZ)公佈,公司於2021年3月4日召開了第五屆董事會第九次會議,審議通過了《關於出售河北中諾醫藥科技有限公司100%股權暨關聯交易的議案》,同意公司以12103萬元向公司控股股東石藥集團恩必普藥業有限公司(“恩必普藥業”)出售河北中諾醫藥科技有限公司(“中諾醫藥科技”)100%股權。同日,公司與恩必普藥業簽署了附條件生效的《股權轉讓協議》,該事項尚需提交公司股東大會審議通過。
中諾醫藥科技為公司子公司河北中諾果維康保健品有限公司停產後所分立新設公司,其已無從事保健食品業務的相關資質及生產能力,目前已基本處於閒置狀態,為進一步整合及優化現有資源配置,盤活資產、回籠資金,聚焦公司核心業務,提升上市公司整體競爭力,公司擬向恩必普藥業出售中諾醫藥科技全部股權。此項交易未構成《上市公司重大資產重組管理辦法》規定的重大資產重組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.